Biolexis Therapeutics
June 18, 2025
Company Presentation
Metabolic Diseases
153A
Biolexis Therapeutics is at the forefront of revolutionizing drug discovery, pioneering next-generation targeted metabolic and regenerative therapies through its proprietary AI-enabled platform, MolecuLern. This transformative technology enables Biolexis to address unmet medical needs in metabolic disorders, obesity, orthopedic recovery, and age-related sarcopenia, positioning the company as a leader in high-impact therapeutic areas. With a robust pipeline of novel therapeutics, strategic clinical development plans, and a focus on addressing growing global healthcare markets, Biolexis is poised to deliver significant clinical and economic value. By integrating AI-driven innovation with a commitment to improving patient outcomes, Biolexis is not only advancing medical science but also contributing to economic growth and public health transformation.
Company HQ City:
Lehi
Company HQ State:
UT
Company HQ Country:
United States
Year Founded:
2021
Lead Product in Development:
Oral Small Molecule GLP-1R Agonist
Oral Small Molecule Isoform Selective AMPK Activator
CEO
David J. Bearss
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
Phase 1 Clinical Trials
What is your next catalyst (value inflection) update?
August 2025
Website
biolexistx.com
Primary Speaker
)
)
){kind=logo}
){kind=logo}
){kind=logo}